Which practice minimizes the risk of mislabeling when collecting samples for ABO grouping?

• A. Label at bedside with patient identifiers
• B. Label at bench after testing
• C. Use a secondary label only
• D. Do not label; rely on barcodes only

Answer: (A)

Preventing mislabeling hinges on labeling the specimen at the bedside with the patient’s identifiers, at the moment of collection. This immediate, patient-present labeling creates a direct link between the person and the sample, reducing opportunities for mixups during collection, transport, or processing. For ABO grouping, where incorrect labeling could lead to life‑threatening transfusion errors, establishing accurate identity before the specimen leaves the collection site is essential.

Labeling later, at the bench after testing, breaks that immediate identity check and opens the door to mismatches, as the sample could be swapped or misidentified during handling. Relying on a secondary label only may omit critical identifiers or become separated from the specimen, increasing confusion and error risk. Not labeling and depending on barcodes alone is unsafe because barcodes can be damaged, scanned incorrectly, or tied to the wrong patient data if the link isn’t solid from the start. By labeling at the bedside with two identifiers (for example, full name and date of birth), you establish a secure, verifiable connection between the patient and the specimen from the outset, which is the best defense against mislabeling.